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Decreased phosphorylation of focal adhesion kinase
(FAK) is associated with loss of focal adhesions and ac-
tin stress fibers and precedes the onset of apoptosis in
renal epithelial cells caused by nephrotoxicants (Van de
Water, B., Nagelkerke, J. F., and Stevens, J. L. (1999)
J. Biol. Chem. 274, 13328–13337). The role of FAK in the
control of apoptosis caused by nephrotoxicants was fur-
ther investigated in LLC-PK1 cells that were stably
transfected with either green fluorescent protein (GFP)-
FAK or dominant negative acting deletion mutants of
FAK, GFP-FAT, and GFP-FRNK. GFP-FAT and GFP-
FRNK delayed the formation of focal adhesions and pre-
vented the localization of endogenous (phosphorylated)
FAK at these sites. GFP-FAT and GFP-FRNK overex-
pression potentiated the onset of apoptosis caused by
the nephrotoxicant dichlorovinyl-cysteine. This was as-
sociated with an increased activation of caspase-3. GFP-
FAT also potentiated apoptosis caused by doxorubicin
but not cisplatin. The potentiation of apoptosis by GFP-
FAT was related to an almost complete dephosphoryl-
ation of FAK; this did not occur in cells overexpressing
only GFP. This dephosphorylation was associated with a
pronounced loss of focal adhesion organization in GFP-
FAT cells, in association with loss of tyrosine phospho-
rylation of paxillin. In conclusion, the data indicate an
important role of cell-matrix signaling in the control of
chemically induced apoptosis; loss of FAK activity
caused by toxic chemicals results in perturbations of
focal adhesion organization with a subsequent inactiva-
tion of associated (signaling) molecules and loss of sur-
vival signaling.
Apoptosis is a highly controlled type of cell death that may
result from severe cellular injury such as due to ischemia/
reperfusion injury, exposure to UV light, -irradiation, as well
as treatment with toxic chemicals (1–3). The response of cells to
such injury is crucial for the outcome of cell damage: cell
survival or death. As a consequence of the cellular injury,
various signaling pathways are (in)activated (4–6). Depending
on the type of signaling cascade cell death is either stimulated
or suppressed. Although some signal transduction cascades,
e.g. growth factor signaling through PKB1 and extracellular
signal-regulated kinase, have been defined to play crucial roles
in the regulation of the cellular response to damage (6, 7), the
role of many other signaling pathways remains largely un-
known. Thus, little is known about the role of disturbances of
the signal transduction pathways mediated by interactions
between cells and the extracellular matrix (ECM) in the cellu-
lar response to injury.
Cell adhesion to ECM through integrin receptors is critical
for normal cell function (8, 9). Perturbation of proper cell-ECM
interactions is observed in various acute and chronic patholog-
ical conditions including ischemia/reperfusion injury, cancer,
as well as exposure to toxic chemicals (10–15). Loss of such
interactions of normal cells results in the onset of apoptosis and
is also referred to as anoikis (16, 17). Altered signaling as a
result of loss of cell-ECM interactions is critical in this process,
and focal adhesion kinase seems to play an important role
(15, 18–21).
Engagement of integrins with the ECM results in activation
of focal adhesion kinase (FAK), a 125-kDa non-receptor tyro-
sine kinase that is localized at focal adhesions, the closest
contacts between cells and the ECM (22). FAK consists of an
N-terminal band 4.1 JEF domain, a central kinase domain, and
a C-terminal so-called focal adhesion targeting (FAT) domain
(22, 23). Upon integrin binding to ECM, FAK is autophospho-
rylated on tyrosine residue 397, which is a docking site for the
SH2 domain of Src family kinases as well as PI 3-kinase (22).
As a consequence of Src binding other tyrosine residues of FAK,
including Tyr576 and Tyr925, are phosphorylated resulting in
increased kinase activity of FAK and additional docking of
other (cytoskeleton-associated) adapter and signaling mole-
cules (22). This coordinated activation of FAK is critical in
diverse cellular processes such focal adhesion formation/turn-
over, cell spreading and migration, cell proliferation, and con-
trol of apoptosis (15, 18–22, 24–27).
There is increasing evidence that FAK is involved in protec-
tion against apoptosis, in particular anoikis. For example, over-
expression of constitutively active FAK prevents anoikis of
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that compete for FAK-integrin association, and also antibodies
directed against FAK itself, can induce apoptosis in fibroblasts
that are not yet fully spread (29). Moreover, treatment of tumor
cells with FAK antisense oligonucleotides or overexpression of
deletion mutants of FAK that only contain the FAT domain and
compete for function of endogenous FAK leads to rounding up
of cells followed by apoptosis (18, 30, 31). During apoptosis
caused by a wide variety of stimuli FAK is cleaved in a caspase-
dependent manner (15, 32–34). This FAK cleavage is seen in
both adherent and non-adherent cell lines. FAK cleavage re-
sults in a C-terminal fragment that contains the FAT domain
and lacks the central catalytic domain of FAK (34). This frag-
ment resembles the protein focal adhesion kinase-related non-
kinase (FRNK) that acts as a dominant negative of FAK and
blocks FAK localization to focal adhesion as well as its phos-
phorylation (25, 34). Therefore, formation of this C-terminal
fragment of FAK during apoptosis may block the anti-apoptotic
function of endogenous FAK (34). Although the above data
indicate an important role for FAK in anoikis, the role of FAK
in chemically induced apoptosis is less well understood. Sonoda
et al. (35) demonstrated that overexpression of FAK in HL60
cells inhibits apoptosis caused by hydrogen peroxide and eto-
poside; however, these cells were non-adherent and had very
low expression levels of endogenous FAK. In addition, the same
group demonstrated that hydrogen peroxide caused increased
phosphorylation of endogenous FAK in T98G cells, which was
related to protection against apoptosis (36, 37). However, these
studies were also performed with suspended cells that lack
normal focal adhesion complexes. Moreover, in these sus-
pended T98G cells FAK phosphorylation levels are negligible,
as expected (36). Thus it still is unknown whether endogenous
FAK in adherent cells (the physiological situation) is critical for
the control of chemically induced apoptosis and whether this is
directly related to changes in the focal adhesion organization.
Moreover, since many chemicals depending on the treatment
conditions cause both necrosis and apoptosis, it remains un-
clear whether there is a difference in regulation of apoptosis
and necrosis by FAK. These issues are part of the present
investigations. For this purpose we used renal proximal tubu-
lar epithelial cells exposed to nephrotoxicants as a model.
Renal proximal tubule epithelial cells (PTCs) are an impor-
tant target for a variety of nephrotoxic medicines, chemicals,
and environmental pollutants as well as ischemia/reperfusion
injury (38–40). Injury of PTCs is associated with detachment of
viable PTCs from the extracellular matrix, both in vitro and in
vivo, an effect that is related to redistribution of integrins,
disturbances of focal adhesion organization, and F-actin orga-
nization (15, 41–47). To investigate the molecular mechanisms
involved in these processes more precisely we have used pri-
mary cultures of rat PTC using the well characterized nephro-
toxicant S-(1,2-dichlorovinyl)-L-cysteine (DCVC) (15, 43, 46–
51). DCVC is metabolized by a cysteine conjugate -lyase to a
reactive acylating metabolite that covalently modifies cellular
macromolecules (48, 52, 53); this bio-activation is required for
the DCVC-induced cytotoxicity both in vivo and in vitro. DCVC
induces both necrosis and apoptosis of PTC, depending on the
treatment conditions (15, 49, 50, 54). It causes formation of
reactive oxygen species that results in lipid peroxidation fol-
lowed by necrosis (48, 54). When lipid peroxidation is blocked
PTCs are protected from necrosis and only apoptosis is allowed
(55). This apoptosis of PTC is preceded by dissolution of focal
adhesion complexes in association with dephosphorylation of
FAK (15, 54). These events are independent of caspase activa-
tion and, importantly, occur well before the onset of caspase-3
activity (15). Based on these findings and the literature data,
we proposed that the loss of FAK activity after toxicant treat-
ment is important for perturbations of focal adhesions organi-
zation as well as FAK-mediated cell survival signaling. To
study this we created renal epithelial cell lines that stably
overexpress dominant negative acting FAK deletion mutants,
FAT and FRNK. Overexpression of these constructs did not
block formation focal adhesion but interfered with endogenous
FAK localization and phosphorylation at focal adhesions. The
data indicate a role for endogenous FAK in the control of
chemically induced apoptosis but not necrosis. This seems di-
rectly related to the role of FAK in focal adhesion organization
and tyrosine phosphorylation of the FAK-associated adapter
protein paxillin. These data show for the first time a role for




Dulbecco’s modified Eagle’s medium, fetal calf serum, G418, penicil-
lin/streptomycin, and trypsin/EDTA were from Life Technologies, Inc.
Bovine serum albumin fraction V, insulin, AMC, doxorubicin, and cis-
platin were from Sigma. Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone was from Bachem (Bubendorf, Switzerland). Acyl-Asp-Glu-Val-
Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) was from Research
Biochemicals Int. (Natick, MA). pEGFP expression plasmids (CLON-
TECH) encoding FAK, and the FAK deletion mutants FAT and FRNK
coupled to green fluorescent protein (GFP) were kindly provided by
Dr. Ilic (see Ref. 18 for detailed description of the constructs). Myc-FAK
was kindly provided by Dr. Hanks. DCVC was synthesized as described
(48).
Cell Culture and Preparation of Stable Transfectants
The porcine renal epithelial cell line LLC-PK1 was from American
Tissue Culture Collection (ATCC) and used between passages 201 and
213. Cells were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% (v/v) fetal calf serum and penicillin/streptomycin
(complete medium) at 37 °C in a humidified atmosphere of 95% air and
5% carbon dioxide. For preparation of stable cell lines, LLC-PK1 cells
were transfected with 0.4 g of DNA of pEGFP, pEGFP-FAK, pEGFP-
FAT, or pEGFP-FRNK using LipofectAMINE Plus reagent according to
the manufacturer’s procedures (Life Technologies, Inc.). Stable trans-
fectants were selected using 800 g/ml G418. Individual clones were
picked and maintained in complete medium containing 100 g/ml
G418. Clones were further analyzed for the expression of the various
GFP chimeras using both flow cytometry, Western blotting, and immu-
nofluorescence. For further experiments for each construct 2–4 individ-
ual stable cell lines were used. For some experiments pkGFP and
pkGFP-FAT clones were transiently transfected with Myc-tagged FAK
in a similar fashion as for the stable transfections.
Cell Treatment Conditions
For cytotoxicity experiments, cells were plated in 15-cm dishes (2106
cells) and grown to subconfluence in 3 days. Thereafter, cells were
trypsinized and plated in collagen-coated 10- or 6-cm dishes at a density
of 0.5–1.105 cells/cm2 in complete culture medium either with or with-
out 10% (v/v) fetal bovine serum. In some experiments cells were plated
in 24-well dishes containing coated glass coverslips (Corning Costar,
Acton, MA). Cells were allowed to adhere and spread overnight. Cells
were treated with DCVC in Hanks’ balanced salt solution (137 mM
NaCl, 5 mM KCl, 0.8 mM MgSO47H2O, 0.4 mM Na2HPO42H2O, 0.4 mM
KH2PO4, 1.3 mM CaCl2, 4 mM NaHCO3, 25 mM HEPES, 5 mM D-glucose,
pH 7.4) in the presence of the antioxidant diphenyl-phenylenediamine
(DPPD; 10 M), which prevents necrosis, for 6 h followed by recovery in
complete medium containing 10 M DPPD. In some experiments cells
were treated with doxorubicin or cisplatin in complete culture medium
without fetal bovine serum.
Determination of Cell Proliferation
For determination of cell proliferation cells were plated in 24-well
dishes at a density of 3104 cells/well, and complete culture medium was
changed every day. At indicated times wells were rinsed twice with
PBS, and after removal of PBS the culture plates were frozen at 20 °C.
After thawing 200 l of MilliQ water was added followed by incubation
for 1 h at 37 °C. After freezing at 80 °C followed by thawing, to 50 l
of sample 50 l of 20 g/ml Hoechst 33258 in TNE (10 mM Tris, 2 M
NaCl, 1 mM EDTA, pH 7.4) was added, and fluorescence was measured























using a plate reader (HTS 7000, PerkinElmer Life Sciences). Calf thy-
mus DNA (Sigma) dissolved in TNE was used as a standard. Cell
number was expressed as amount DNA/well.
Determination of Cell Death
Cell Cycle Analysis—Apoptosis was determined by cell cycle analysis
as described (18). Briefly, floating and adherent cells that were
trypsinized were pooled and subsequently fixed in 90% ethanol
(20 °C). After washing cells twice with PBS, 1 mM EDTA cells were
resuspended in PBS/EDTA containing 7.5 M propidium iodide and 10
g/ml RNase A. After 30 min incubation at room temperature the cell
cycle was analyzed by flow cytometry (FACS-Calibur, Becton Dicken-
son), and the percentage of cells present in sub-G0/G1 was calculated
using the Cellquest software (Becton Dickenson).
Annexin V Staining—In some experiments apoptosis was determined
by staining with fluorescent-labeled annexin V and propidium iodide.
Briefly, floating as well as adherent cells that were trypsinized were
pooled and centrifuged for 5 min at 500  g. Pelleted cells were resus-
pended and allowed to recover for 30 min in complete culture medium.
Thereafter, cells were centrifuged again for 5 min at 500  g and
resuspended in 100 l of annexin-V binding buffer (10 mM HEPES, 145
mM NaCl, 5 mM KCl, 1 mM MgCl26H2O, 1.8 mM CaCl22H2O, pH 7.4)
containing allophycocyanin-conjugated annexin-V followed by incuba-
tion on ice for 15 min. After addition of 100 l of binding buffer
containing 10 M propidium iodide, cells were analyzed by flow cytom-
etry. The percentage of cells that were either annexin-V-positive and
propidium iodide-negative (AV/PI; i.e. apoptotic cells) or annexin-V-
positive and propidium iodide-positive (AV/PI; i.e. necrotic cells)
was calculated using the Cellquest software.
Lactate Dehydrogenase (LDH) Release—Necrotic cell death was
measured by the release of LDH from cells in the culture medium as
described (47). The percentage of cell death was calculated from the
amount of LDH release caused by treatment with toxicants relative to
the amount to that released by 0.1 w/v Triton X-100, i.e. 100% release.
Caspase activity was assayed as follows. Briefly, attached and de-
tached cells were harvested and collected by centrifugation as above.
The cell pellet was taken up in lysis buffer (10 mM HEPES, 40 mM
-glycerophosphate, 50 mM NaCl, 2 mM MgCl2, and 5 mM EGTA, pH 7.4)
and subjected to three cycles of freezing and thawing. Equal amounts of
cell proteins were used in a caspase assay using Ac-DEVD-AMC (25 M;
Research Biochemicals Int.) as a substrate. Fluorescence derived from
release of the AMC moiety was followed using a fluorescence plate
reader (HTS 7000; PerkinElmer Life Sciences). Caspase activity was
calculated as pmol/mg cell proteinmin using AMC as a standard.
Gel Electrophoresis and Immunoblotting
For Western blot analysis cells were scraped in ice-cold TSE (10 mM
Tris, 250 mM sucrose, 1 mM EGTA, pH 7.4) plus inhibitors (50 mM NaF,
1 mM Na3VO4, 10 g/ml leupeptin, 10 g/ml pepstatin, 1 mM phenyl-
methylsulfonyl fluoride, and 1 mM dithiothreitol) and pooled with the
floating cells. Protein concentration was determined using the Bradford
protein assay using IgG as a standard. Equal amounts of total cellular
protein were separated by SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride membrane (Millipore). Blots
were blocked with 5% (w/v) non-fat dry milk in TBS-T (0.5 M NaCl, 20
mM Tris-HCl, 0.05% v/v Tween 20, pH 7.4) and probed with the appro-
priate antibodies as follows: anti-PARP (monoclonal C2.10, 1:2,000;
Enzyme System Products), anti-FAK (clone 77 directed against resi-
dues 354–533 of FAK, 1 g/ml, Transduction Laboratories; or poly-
clonal antibody directed against the C-terminal residues 748–1053 of
FAK, 1 g/ml, Upstate Biotechnology, Inc.), anti-paxillin (clone 349, 0.5
g/ml, Transduction Laboratories), phospho-state-specific anti-PY397-
FAK (0.25 g/ml, BIOSOURCE Int.), and phospho-state-specific anti-
PY118-paxillin (0.25 g/ml, BIOSOURCE Int.). For detection of FAK
and paxillin, the appropriate horseradish peroxidase-coupled secondary
antibodies (The Jackson Laboratories) and ECL reagent were used
(Amersham Pharmacia Biotech). For phospho-state-specific antibody
detection the Tropix kit was used (PerkinElmer Life Sciences).
Immunofluorescence and Imaging Techniques
For immunofluorescence studies cells were cultured on collagen-
coated glass coverslips in 24-well dishes. Cells were fixed with 3.7%
formaldehyde for 10 min followed by 3 washes with PBS. In some
experiments cells were fixed in 20 °C methanol for 5 min followed by
3 washes with PBS. After cell permeabilization and blocking with PBS,
0.2% w/v Triton X-100, 0.5% (w/v) bovine serum albumin, pH 7.4 (PTB),
cells were stained for FAK (mouse monoclonal clone 77, 1 g/ml, Trans-
duction Laboratories; or polyclonal antibody directed against the C
terminus, 1 g/ml, Upstate Biotechnology, Inc.) and PY397-FAK (phos-
pho-state-specific anti-PY397-FAK, 1 g/ml, BIOSOURCE Int.). Cells
were also stained against paxillin (1 g/ml, Transduction Laboratories)
and PY118-paxillin (phospho-state-specific PY118-paxillin, 1 g/ml, BIO-
SOURCE Int.) diluted in PTB. After transient transfection with myc-
FAK cells were immunostained for Myc (mouse monoclonal clone 9E10,
1 g/ml, Roche Molecular Biochemicals). For secondary staining Cy3-
labeled goat anti-rabbit and Cy5-labeled goat anti-mouse antibodies
were used (1 g/ml, The Jackson Laboratories). Cells were mounted on
glass slides using Aqua-Poly/Mount (Polysciences Inc., Warrington,
PA). Cells were viewed using a modified Bio-Rad 600 MRC confocal
laser scanning microscope, and GFP, Cy3, and Cy5 staining was ana-
lyzed using the 488, 543, and 633 nm lasers, respectively, in combina-
tion with the appropriate excitation/emission filter sets. For clarity
negative images of the original collected images are shown.
Statistical Analysis
Student’s t test was used to determine if there was a significant
difference between two means (p  0.05); statistical differences are
indicated with an asterisk. When multiple means were compared, sig-
nificance was determined by a one-way analysis of variance (p  0.05)
in conjunction with a Newman Keul’s post hoc test. For analysis of
variance, letter designations are used to indicate significant differences.
Means with a common letter designation are not different; those with a
different letter designation are significantly different from all other
means with different letter designations.
RESULTS
Characterization of LLC-PK1 Cells Overexpressing GFP-
FAK, GFP-FRNK, and GFP-FAT—To investigate the role of
FAK in apoptosis of renal epithelial cells caused by nephrotoxic
xenobiotics, we used the LLC-PK1 cell line, which is of renal
proximal tubular cell origin. These cells are often used as a
model to study mechanisms of renal cytotoxicity; the mecha-
nism of toxicity of DCVC is similar in primary cultured renal
proximal tubular cells and LLC-PK1 cells (49, 55). First we
created stable cell lines of LLC-PK1 cells that overexpress
deletion mutants of FAK, either FAT or FRNK (Fig. 1A). These
mutants act as dominant negatives and compete for localiza-
tion of FAK at focal adhesions (18). In addition, we created cell
lines with stable overexpression of FAK. We used GFP expres-
sion constructs to facilitate clonal selection and characteriza-
tion of the clonal derivatives. Furthermore, the use of GFP
constructs allows us to follow focal adhesion organization and
other biochemical events in living cells. GFP-FAT and GFP-
FRNK chimeric proteins behave in a similar fashion as FAT
and FRNK proteins (18). Four clonal derivatives of GFP, GFP-
FAT, and GFP-FAK and two clonal derivatives of GFP-FRNK
were obtained (Fig. 1). All clones expressed either GFP or GFP
chimeras as determined by flow cytometric analysis, yet the
mean GFP fluorescence intensity varied between the various
constructs (Fig. 1B). Expression of GFP or GFP chimeras was
in over 95% of the cells for all clones. The GFP-FAK, -FAT, and
-FRNK chimeras had the expected molecular weight as de-
tected by Western blotting using a polyclonal anti-FAK anti-
body directed against the C terminus of FAK (Fig. 1C) and an
anti-GFP antibody (not shown). Importantly, the amount of
transfected FAT and FRNK present in the cells was well above
the levels of endogenous FAK. Overexpression of GFP-FAT or
-FRNK did not affect the expression of endogenous FAK; some-
what increased FAK levels were found in pkGFP-FAK cells
(Fig. 1D) possibly due to breakdown of GFP-FAK. None of the
constructs affected expression of other focal adhesion-associ-
ated cytoskeletal proteins, including paxillin and p130Cas. In
addition, no difference in the expression of Pyk2 was observed
between the different clones (Fig. 1D), although an increased
expression in fibroblasts deficient in FAK has been reported
(56).
GFP-FAT Delays Focal Adhesion Formation of LLC-PK1























Cells—The FAT domain of FAK is involved in the localization
of FAK to focal adhesions through interactions with other focal
adhesion-associated cytoskeletal proteins, including talin and
paxillin (22). Previous studies in avian and mammalian fibro-
blasts and endothelial cells demonstrated that FRNK competes
for the localization of FAK at focal adhesion and the organiza-
tion of focal adhesion structures. Therefore, we tested whether
GFP-FAT also inhibited cell spreading and focal adhesion or-
ganization. No statistical difference was observed between the
percentage of spread cells for the GFP and GFP-FAT clones at
2, 4, or 24 h either in the presence or absence of serum (Table
I). Next we determined whether GFP-FAT inhibited focal ad-
hesion formation. At 4 h after plating GFP cells had formed
focal adhesion structures as determined by accumulation of
paxillin in structures that resemble focal adhesions (Fig. 2).
Despite the fact that GFP-FAT was unable to block cell spread-
ing, the early formation of focal adhesions was inhibited (Fig.
2). In pkGFP cells phosphorylated FAK (i.e. PY397-FAK) was
localized at focal adhesions. This was not observed in pkGFP-
FAT cells. Several other focal adhesion-associated proteins,
including paxillin, are located at focal adhesions and phospho-
rylated on tyrosine residues during cell spreading. Therefore,
we also immuno-stained cells for phosphotyrosine (PY). In GFP
cells PY staining was clearly visible at focal adhesions. PY
staining was also observed in GFP-FAT cells, but it was not
present in distinct sites resembling focal adhesions but rather
as a broad band at the lamellipodia of spreading cells (Fig. 2).
GFP-FAT Competes for the Localization and Phosphoryla-
tion of FAK at Focal Adhesions—Previous studies of fibroblasts
had indicated that FRNK only retards cell spreading and focal
adhesion formation (25). Moreover, nullizygous FAK fibro-
blasts still form focal adhesions (56). We also determined
whether FAT affected focal adhesion formation at later time
points. In pkGFP cells 24 h after plating FAK and PY397-FAK
were clearly detectable at focal adhesions (Fig. 4A), which
correlated with a phosphorylation of FAK as determined by
Western blotting (Fig. 3). In pkGFP-FAT cells GFP-FAT was
located at sites resembling focal adhesions. Despite the fact
that there was still a considerable amount of PY397-FAK pres-
ent in pkGFP-FAT cells (Fig. 3), hardly any staining of FAK
and PY397-FAK was detected at focal adhesions as determined
by immunofluorescent staining (Fig. 4A). Similar observations
were made with either formaldehyde or methanol fixation or
with different FAK antibodies (data not shown). Although the
above indicate a displacement of FAK from focal adhesions by
GFP-FAT, the possibility existed that GFP-FAT prevents im-
munofluorescent detection of FAK at these sites due to steric
hindrance. To exclude this possibility we used two different
approaches. First, cells were fixed with either formaldehyde or
methanol followed by double staining for FAK with another
focal adhesion-associated protein, either paxillin or vinculin. In
pkGFP cells FAK and paxillin clearly co-localized at focal ad-
TABLE I
Effect of GFP-FAT on cell spreading
Cells were plated on collagen-coated coverslips and allowed to adhere
in the presence or absence of 10% (v/v) fetal bovine serum. After 2, 4, or
24 h cells were fixed, and the percentage of spread cells was determined
by phase contrast microscopy. Data shown are the mean  S.D. of four
independent clones (n  4) and are representative for two different
experiments. A–D indicate significant differences. Statistical differ-
ences were determined as described under “Experimental Procedures.”
ND, not determined.
% cell spreading
2 h 4 h 24 h
GFP
Plus serum 61  4A 80  2B 90  1D
Minus serum ND 35  7C 73  8D
GFP-FAT
Plus serum 49  7A 69  3B 87  1D
Minus serum ND 28  5C 75  7D
FIG. 1. Characterization of LLC-PK1 cells stably expressing GFP, GFP-FAT, GFP-FRNK, and GFP-FAK. A, LLC-PK1 cells were
transfected with constructs containing GFP, GFP-FAT, GFP-FRNK, or GFP-FAK. B, stable clones were characterized by flow cytometric analysis
for the average GFP fluorescence (y axes) and percentage of GFP-positive cells within the population (numbers above bars). Shown is mean  S.D.
of the relative mean GFP fluorescence intensity (FL1 detector) of four independent clones for each construct, except for GFP-FRNK where only two
clones were obtained. C, size of the various constructs was checked by Western blotting (IB) using an anti-FAK antibody directed against the C
terminus of FAK. Shown are representative clones for pkGFP (clone 7), pkGFP-FAK (clone 4), pkGFP-FRNK (clone 1), and pkGFP-FAT (clone 8).
D, expression levels of FAK, paxillin, Pyk2, and p130Cas in pkGFP (clone 7 and 11), pkGFP-FAK (clone 4 and 5), pkGFP-FRNK (clone 1 and 2), and
pkGFP-FAT (clone 6 and 8) were determined by Western blotting. For reasons of space only two clones for each construct are shown. Data shown
are representative for the other clones.























hesions. However, despite the fact that in pkGFP-FAT cells
paxillin was clearly present at focal adhesions, little FAK was
observed at the same sites (Fig. 5A). Similar observations were
made for vinculin staining (data not shown). In a second ap-
proach, both pkGFP and pkGFP-FAT cells were transiently
transfected with Myc-tagged FAK, and after 24 h cells were
fixed and stained for Myc and GFP. We anticipated that in
pkGFP-FAT cells at least some of the expressed Myc-FAK
protein would be localized at focal adhesions. If GFP-FAT
would indeed cause steric locking thereby preventing immuno-
detection of antigens in the close proximity of GFP-FAT, then
no Myc-FAK detection would be expected at the focal adhe-
sions. However, in contrast, in pkGFP as well as pkGFP-FAT
cells Myc staining was observed at sites resembling focal
adhesions. Most important, in pkGFP-FAT cells Myc-FAK
co-localized with GFP at focal adhesions (Fig. 5B). The FAT
domain of FAK is required for the interactions with the
adapter protein paxillin (22). FAK seems involved in the
phosphorylation of paxillin on tyrosine residues 31 and 118
(57, 58). Although the above already indicated the correct
localization of paxillin at focal adhesions in pGFP-FAT cells,
the possibility existed of an altered phosphorylation of pax-
illin due to loss of FAK at focal adhesions in pkGFP-FAT
cells. To this end we determined in pkGFP-FAT cells whether
both paxillin and phosphorylated paxillin were still present
at focal adhesions. Therefore, cells were co-stained for paxil-
lin as well as PY118-paxillin. Despite the fact that FAK was
no longer present at focal adhesions in pkGFP-FAT cells,
paxillin co-localized with GFP-FAT and was also still phos-
phorylated on tyrosine residue 118 (Fig. 4B).
In conclusion, the combined above observations indicate that
overexpression of GFP-FAT in LLC-PK1 cells slows, but does
not block, the formation of focal adhesions; it competes for the
localization of FAK and, consequently, localization of PY397-
FAK on focal adhesions.
GFP-FAT Potentiates Apoptosis Caused by S-(1,2-Dichlorovi-
nyl)-L-cysteine (DCVC)—Recently we showed that several
nephrotoxicants, including DCVC, cause dephosphorylation of
FAK, which precedes the onset of apoptosis, e.g. caspase acti-
vation and caspase-mediated cleavage of FAK (15). Since GFP-
FAT competes for FAK localization and some of its function in
LLC-PK1 cells (see above), we used these cells to investigate
whether FAK is involved in controlling nephrotoxicant-induced
apoptosis in renal epithelial cells. pkGFP and pkGFP-FAT cells
were plated on collagen-coated dishes followed by overnight
culturing to ensure that both cell lines had formed normal focal
adhesion plaques (see above). Thereafter, cells were treated
with DCVC and assessed for apoptosis. GFP-FAT overexpres-
sion clearly potentiated the DCVC-induced apoptosis of renal
epithelial cells as determined by analyzing phosphatidylserine
externalization using annexin V-allophycocyanin/propidium
iodide staining (Fig. 6, A–D) or by cell cycle analysis (Fig. 6E).
The onset of apoptosis in pkGFP-FAT cells was already ob-
served after 8 h. After 24 h there was still a difference in the
percentage of apoptotic cells between pkGFP and pkGFP-FAT
cells (Fig. 6E).
Potentiation of DCVC-induced Apoptosis by FAT Involves
Activation of Caspase-3—Caspase-3 is required for activation of
endonucleases as well as the cleavage of various caspase sub-
strates during apoptosis, including PARP. Therefore, we next
investigated whether the potentiation of apoptosis as deter-
mined by flow cytometric analysis was associated with the
more rapid onset of caspase-3 activity. Indeed, GFP-FAT over-
expression accelerated the onset of caspase-3-like activity in a
time- and concentration dependent manner (Fig. 7, A and B).
This increased activity was directly related to a higher percent-
age of cells that was positive for active caspase-3 as determined
by immunofluorescence staining (Fig. 7C; data not shown). The
increased activity of caspase-3 in GFP-FAT cells was also as-
sociated with a more rapid onset of the formation of active
caspase-3 and cleavage of the typical caspase-3 substrate PARP
(Fig. 7D). In conclusion, the data indicate that GFP-FAT sen-
FIG. 3. Effect of GFP-FAT on phosphorylation of FAK. pkGFP
and pkGFP-FAT cells were plated on collagen-coated 10-cm dishes
followed by 24-h recovery in culture medium with or without 10% (v/v)
fetal bovine serum. Thereafter, cells were scraped in TSE plus inhibi-
tors, and equal amounts of proteins were separated by SDS-polyacryl-
amide gel electrophoresis followed by transfer to polyvinylidene diflu-
oride membranes and staining for FAK and PY397-FAK. Shown are the
data from pkGFP (clone 7) and pkGFP-FAT (clone 8), which are repre-
sentative for other clonal derivatives.
FIG. 2. Effect of GFP-FAT on focal
adhesion formation and FAK phos-
phorylation. pkGFP and pkGFP-FAT
cells were plated on collagen-coated cov-
erslips in complete culture medium, and
4 h after plating cells were fixed and
stained for either paxillin, PY397-FAK, or
phosphotyrosine (PY) followed by analy-
sis by confocal laser scan microscopy.
Shown are images from pkGFP (clone 7)
and pkGFP-FAT (clone 8) that are repre-
sentative for the other clones. Note the
formation of focal adhesion (paxillin
staining) in pkGFP cells but not in
pkGFP-FAT cells. These focal adhesions
contain PY397-FAK as well as phospho-
tyrosine. GFP-FAT cells contain concen-
trated regions of phosphotyrosine in la-
mellipodia but not in focal adhesion-like
structures.























sitizes cells to undergo apoptosis by accelerating the activation
of caspase-3.
FAK Signaling Is Not Involved in DCVC-induced Necrosis—
DCVC-induced cytotoxicity is a continuum between necrosis
and apoptosis (15, 55); both types of cell death share the same
bio-activation pathway (15, 55). DCVC-induced necrosis in-
volves the initiation of lipid peroxidation (48, 54). By inhibiting
lipid peroxidation using a lipid radical scavengers, i.e. DPPD as
in the above experiments, we follow apoptosis caused by DCVC
more selectively (15, 49, 50, 55). Likewise, by omitting DPPD
from the culture medium we can investigate the mechanisms of
DCVC-induced necrosis. By using this switch we wanted to
answer the question whether FAK signaling is involved in both
DCVC-induced necrosis and apoptosis. Therefore, pkGFP and
pkGFP-FAT cells were treated with DCVC in the presence or
absence of DPPD. Necrosis was determined by measuring the
release of LDH from the cells. DCVC clearly caused the release
of LDH in pkGFP cells; as expected this was blocked by the
antioxidant DPPD (Fig. 8). No significant difference was ob-
served between the LDH release caused by DCVC in pkGFP
and pkGFP-FAT cells (Fig. 8), indicating that FAK plays no
role in controlling necrosis in chemically induced cytotoxicity.
GFP-FAK Overexpression Does Not Protect against DCVC-
induced Apoptosis—The above investigations indicated that
blocking FAK function by overexpressing GFP-FAT leads to
increased sensitivity of LLC-PK1 cells toward DCVC-induced
apoptosis. To investigate whether blocking FAK function by
other means also results in an increase of DCVC-induced apo-
FIG. 4. GFP-FAT prevents localization of FAK and PY397-FAK
at focal adhesions. pkGFP and pkGFP-FAT cells were plated on
collagen-coated coverslips and allowed to adhere and spread for 24 h.
Thereafter, cells were fixed, followed by immunofluorescent staining for
either FAK and PY397-FAK (A) or paxillin and PY118-paxillin (B). Lo-
calization of GFP or GFP-FAT (GFP; 488 nm laser), PY397-FAK or
PY118-paxillin (Cy3; 543 nm laser), and FAK or paxillin (Cy5; 633 nm
laser) were analyzed by confocal laser scan microscopy. Data shown are
from pkGFP (clone 7) and pkGFP-FAT (clone 8) that are representative
for the various pkGFP and pkGFP-FAT clones. Note that in GFP-FAT
cells FAK and PY397-FAK are no longer located at sites resembling focal
adhesions (A). In addition, focal adhesions in pkGFP and pkGFP-FAT
cells are normally formed, as judged by staining for paxillin and PY118-
paxillin (B).
FIG. 5. GFP-FAT does not disrupt paxillin and myc-FAK local-
ization at focal adhesions. A, pkGFP and pkGFP-FAT were plated on
collagen-coated coverslips in complete medium and allowed to adhere
for 24 h. Thereafter, cells were fixed and co-immuno-stained for FAK
and paxillin followed by analysis by confocal laser scan microscopy. B,
pkGFP and pkGFP-FAT cells were transfected with Myc-tagged FAK as
described under “Experimental Procedures.” 24 h after transfection
cells were fixed and immunostained for Myc followed by confocal laser
scan microscopy. Note the co-localization of Myc-FAK and GFP-FAT in
pkGFP-FAT cells.























ptosis and whether overexpression of GFP-FAK inhibits
DCVC-induced apoptosis, cells expressing GFP-FRNK or GFP-
FAK were treated with DCVC, and the effect on apoptosis was
analyzed. Like GFP-FAT, overexpression of GFP-FRNK poten-
tiated the induction of apoptosis caused by DCVC. Overexpres-
sion of GFP-FAK did not protect against apoptosis caused by
DCVC (Table II).
Differential Regulation of Doxorubicin and Cisplatin-in-
duced Apoptosis by FAK—To investigate whether modulation
of apoptosis by FAK is a common mechanism for nephrotoxi-
cant-induced apoptosis, pkGFP and pkGFP-FAT cells were
treated with various concentrations of either doxorubicin or
cisplatin. FAT overexpression significantly increased the sen-
sitivity against doxorubicin-induced apoptosis of these cells
(Fig. 9A). However, no significant difference was observed with
regard to cisplatin-induced apoptosis between pkGFP and
pkGFP-FAT cells (Fig. 9B).
GFP-FAT Potentiates Anoikis of LLC-PK1 Cells—FAK-medi-
ated signals are central in the control of adhesion-mediated cell
survival. Likewise, loss of cell adhesion results in loss of FAK
signaling and induction of apoptosis, which is also termed
anoikis. We hypothesized that perturbation of FAK function by
overexpressing GFP-FAT should also enhance the sensitivity of
cells toward anoikis. To test this hypothesis the various clones
were trypsinized, and cells were plated on agarose-coated
dishes to prevent cell adhesion; apoptosis was determined by
cell cycle analysis. GFP-FAT expression significantly increased
the induction of anoikis compared with GFP cells. Similar
observations were made for GFP-FRNK cells (Table III). These
data suggest that there is, at least in part, an overlap in the
FIG. 6. Effect of GFP-FAT on DCVC-
induced apoptosis. pkGFP and pkGFP-
FAT cells were plated on collagen-coated
6-cm dishes in serum-free culture me-
dium and after overnight attachment
cells were treated with DCVC (0.25 mM)
in Hanks’/HEPES buffer containing 10
M DPPD for 6 h followed by recovery in
complete medium containing 10 M
DPPD. After 8 h cell death was analyzed
by annexin-V/propidium iodide (AV/PI)
staining in untreated pkGFP-FAT (clone
8) cells (A) and cells treated with DCVC
(B). The percentage of apoptotic cells
(AV/PI) (C) and necrotic cells (AV/
PI) (D) was calculated for the different
GFP and GFP-FAT clones. For cell cycle
analysis (E) samples were taken at 4, 8,
12, and 24 h after treatment with DCVC,
and apoptosis was determined as de-
scribed under “Experimental Proce-
dures.” Data shown (C–E) are mean 
S.D. of four independent clones for each
construct (n  4). The data are represent-
ative for two independent experiments.
FIG. 7. Effect of GFP-FAT on caspase-3 activation and PARP cleavage caused by DCVC. pkGFP and pkGFP-FAT cells were treated with
DCVC as described in Fig. 6. For DEVDase activity cells were treated with DCVC (0.25 mM), and samples were analyzed at the indicated time
points (A). In another experiment cells were treated with different concentration of DCVC, and DEVDase activity was determined at 10 h (B).
DEVDase activity shown is mean  S.D. for four independent clones (n  4). Data are representative for two different experiments. Caspase-3
activation was analyzed by immunofluorescence using an anti-active caspase-3 antibody (C). Cells that were plated on collagen-coated coverslips
were either left untreated (top panel) or treated with DCVC (0.25 mM), 10 M DPPD (lower panel) for 8 h. Thereafter, cells were fixed and processed
for immunofluorescence followed by confocal laser scan microscopy. Shown is a representative field of pkGFP-FAT (clone 8). This clone is
representative for other pkGFP-FAT clones. D, caspase-3 processing and PARP cleavage was determined by Western blotting. Cells were treated
as in A. Polyvinylidene difluoride membranes were probed with either anti-active caspase-3 or anti-PARP. Data shown are for pkGFP (clone 7) and
pkGFP-FAT (clone 8) and representative for other pkGFP and pkGFP-FAT clones, respectively. The data are representative for two different
experiments.























signals that control chemically induced apoptosis and anoikis
of LLC-PK1 cells.
GFP-FAT Overexpression Potentiates Loss of FAK Phospho-
rylation and Focal Adhesion Organization—Focal adhesion or-
ganization is dependent on FAK phosphorylation. Although
almost all of endogenous FAK was no longer present at focal
adhesions there was still a substantial amount of FAK phos-
phorylation on Tyr397 (see Fig. 3). We reasoned that if GFP-
FAT affects the function of endogenous FAK, then the poten-
tiation of apoptosis caused by DCVC should be related to a
more pronounced loss of FAK phosphorylation. Indeed, phos-
phorylation of endogenous FAK was almost completely lost in
pkGFP-FAT cells after treatment with DCVC; this was not the
case in pkGFP cells (Fig. 10).
In primary cultured renal proximal tubular cells DCVC-
induced dephosphorylation of FAK is associated loss of focal
adhesion organization (18). We hypothesized that if there is a
direct relationship between loss of FAK phosphorylation and
focal adhesion organization after cellular injury, then focal
adhesion organization should be more affected by DCVC in
pkGFP-FAT cells than in pkGFP cells. To investigate this
pkGFP and pkGFP-FAT cells were double-stained for PY118-
paxillin and paxillin. PY118-paxillin is primarily located at focal
adhesion and, therefore, a good measure for focal adhesion
organization. Treatment of pkGFP cells with DCVC for 8 h
resulted in a minor loss of focal adhesion complexes as deter-
mined by PY118 paxillin/paxillin staining (Fig. 11). In contrast,
in pkGFP-FAT cells treatment with DCVC resulted in an al-
most complete loss of focal adhesions (Fig. 11). These findings
were confirmed by analyzing the levels of paxillin phosphoryl-
ation on Tyr31 and Tyr118 by Western blotting. Thus, tyrosine
phosphorylation of paxillin was almost completely lost in
pkGFP-FAT cells treated with DCVC, whereas most of it was
still present in pkGFP cells after treatment with DCVC
(Fig. 12).
DISCUSSION
The present investigations on the role of FAK in chemically
induced perturbations of focal adhesion organization and onset
of cell death (i.e. apoptosis and necrosis) allow us to draw
several conclusions. First, the data indicate an important role
for FAK in chemically induced apoptosis in adherent cells.
Thus, overexpression of deletion mutants of FAK, namely FAT
and FRNK, which both compete with endogenous FAK for
localization to focal adhesions, accelerated the onset of apopto-
sis caused by DCVC. A similar finding was observed for doxo-
rubicin that has a different mechanism of action than DCVC.
In contrast, cisplatin-induced apoptosis of LLC-PK1 cells was
not potentiated. Thus, FAK has a protective role against apo-
ptosis caused by at least some, but not all, chemicals. To our
knowledge this is the first report that indicates that FAK
provides protection in chemically induced apoptosis in adher-
ent cells. Second, FAK does not seem to play a role in the
control of chemically induced necrosis. Although overexpres-
sion of FAT accelerated the onset and extent of DCVC-induced
apoptosis, no effect was observed on the induction of necrosis.
Both apoptosis and necrosis caused by DCVC require the same
bioactivation by -lyase (15, 48, 54, 55). The fact that the extent
of necrosis is similar in pkGFP and pkGFP-FAT cells indicates
that the degree of cell injury in both cell types is most likely the
same, which would exclude the possibility that the increased
apoptosis caused by DCVC in pkGFP-FAT is due to an in-
creased bio-activation. Third, FAK seems important in the
maintenance of focal adhesion organization after cellular in-
jury. Treatment of LLC-PK1 cells resulted in loss of focal ad-
hesion organization as assessed by staining of cells against
paxillin and phospho-paxillin (Fig. 11). Although the organiza-
tion of focal adhesion organization in untreated cells was not
affected by GFP-FAT, treatment with DCVC caused a dramatic
loss of focal adhesion in pkGFP-FAT cells but not in pkGFP
cells. This effect strongly correlated with a rapid loss of the
levels of FAK phosphorylation on tyrosine residue 397. Impor-
tantly, loss of focal adhesion organization occurred prior to
activation of caspase-3. These observations are in accordance
with our previous findings (15) in primary cultured rat renal
proximal tubular epithelial cells where a complete loss of focal
adhesion as well as FAK phosphorylation occurs prior to the
onset of apoptosis. The combined data fit a model whereby
toxicant-induced perturbation of FAK phosphorylation causes
disturbances of focal adhesion organization and loss of phos-
phorylation of focal adhesion-associated adapter proteins, such
as paxillin, most likely resulting in loss of signaling cascades
that otherwise suppress apoptotic routes.
Our data indicate that GFP-FAT and GFP-FRNK delay the
early but not the late formation of focal adhesions in LLC-PK1
cells. These data are consistent with those obtained by other
investigations. Thus, transient overexpression of FRNK in
avian fibroblast also delayed the formation of focal adhesions
(25). In several breast tumor cell lines retrovirally mediated
overexpression of a FAK C-terminal domain construct caused
FIG. 8. Effect of GFP-FAT on DCVC-
induced necrosis. pkGFP and pkGFP-
FAT cells were treated with DCVC in
Hanks’/HEPES buffer at the indicated
concentration either with or without
DPPD (10 M). At 4 and 8 h the percent-
age of % LDH release was determined as
described under “Experimental Proce-
dures.” Data shown are the means  S.D.
of four independent clone for each con-
struct (n  4). Data are representative for
two independent experiments.
TABLE II
Effect of GFP-FAK and GFP-FRNK on DCVC-induced apoptosis
Cells were plated on collagen-coated dishes and allowed to adhere
and spread overnight. Thereafter cells were treated with DCVC (0.25
mM) in Hanks’/HEPES buffer containing 10 M DPPD for 8 h followed
by 4 h of recovery in medium. Apoptosis was determined by cell cycle
analysis using flow cytometry as described under “Experimental Pro-
cedures.” Data shown are the mean  S.E. of four different clones (n 




GFP 2  1Aa 31  4B
GFP-FAK 3  1A 27  4B
GFP-FRNK 4/6b 46/50b
GFP-FAT 4  1A 62  5C
a Statistical differences were determined as described under “Exper-
imental Procedures.”
b Data shown are from two individual GFP-FRNK clones.























not only perturbations of focal adhesion organization but also
led to rounding up of cells followed by apoptosis (31). This was
associated with dephosphorylation of FAK (31). The fact that
this was not observed in our system is most likely due to the
fact that we have made stable cell lines that may have lower
expression levels of dominant negative-acting FAK compared
with transient retrovirally mediated transfection. Thus, most
likely, only LLC-PK1 cells with relatively lower levels of GFP-
FAT or GFP-FRNK that were still able to form focal adhesions
at later stages and grow normally may have been selected.
Despite the fact that FAK was no longer detectable at focal
adhesion in pkGFP-FAT cells, the levels of PY397-FAK as de-
termined by Western blotting were comparable between
pkGFP and pkGFP-FAT cells. This may explain the fact that no
difference in the background apoptosis was observed between
pkGFP and pkGFP-FAT cells.
We found that increased expression of GFP-FAK did not
provide protection against chemically induced apoptosis. Sim-
ilar findings were found in rabbit synovial fibroblast (18). In
contrast, in HeLa cells overexpression of FAK protects almost
completely against apoptosis caused by either hydrogen perox-
ide or etoposide (35). In Madin-Darby canine kidney cells over-
expression of constitutively active FAK also protects against
UV-induced apoptosis (21). These differences might be ex-
plained by the fact that HeLa cells themselves contain very low
levels of endogenous FAK; moreover, HeLa cells are non-ad-
herent cells. In contrast both the rabbit synovial fibroblast and
our own LLC-PK1 cells are adherent cells that already possess
endogenous FAK that is phosphorylated. Although in our
hands pkGFP-FAK cells contain high levels of phosphorylated
GFP-FAK, most of the phosphorylated GFP-FAK was not pres-
ent in focal adhesion (data not shown). Moreover, importantly,
our initial findings indicate that the levels of phosphorylation
of PKB/Akt, which lies downstream from FAK and is involved
in cell-ECM-mediated survival signaling, are similar in pkGFP
and pkGFP-FAK cells.2 This suggests that the levels of endog-
enous FAK are already sufficient to provide the maximal sur-
vival signals and that more FAK, i.e. GFP-FAK, does not nec-
essary lead to increased survival. However, in pkGFP-FAT
cells introduction of more FAK by transfection of wild type FAK
might overrule the enhancement of the apoptosis caused by
GFP-FAT. Unfortunately, such experiments seemed impossible
since overexpression of Myc-tagged FAK by transient transfec-
tion in pkGFP-FAT cells did not alleviate localization of GFP-
FAT from focal adhesions (Fig. 5B), thereby making the eval-
uation of an effect of FAK overexpression on GFP-FAT-
mediated potentiation of apoptosis difficult.
Our previous studies (15) in primary cultured rat PTC indi-
cated that toxicant-induced perturbations of the localization of
FAK at focal adhesions coincided with an overall loss of FAK
phosphorylation and focal adhesion disruption. A causal rela-
tionship between FAK dephosphorylation and focal adhesion
organization could not be established (15). Our present data
show that in pkGFP-FAT cells the DCVC-induced focal adhe-
sion disruption occurs much faster than in pkGFP cells (Fig.
11). This is consistent with the fact that FAK levels at focal
2 B. van de Water and I. Tijdens, manuscript in preparation.
FIG. 9. Effect of GFP-FAT on apo-
ptosis of LLC-PK1 cells caused by ei-
ther doxorubicin or cisplatin. pkGFP
and pkGFP-FAT cells were treated with
the indicated concentrations of doxoru-
bicin or cisplatin in complete culture me-
dium. After 24 h apoptosis was analyzed
by cell cycle analysis as described under
“Experimental Procedures.” Data shown
are the means  S.D. of four independ-
ent clone for each construct (n  4). Data
are representative for two independent
experiments.
TABLE III
Effect of GFP, GFP-FAT, GFP-FRNK, and GFP-FAT on
anoikis of LLC-PK1 cells
Cells were trypsinized and either plated on collagen- or agarose-
coated 6-cm dishes. After 16 h cells were harvested, and apoptosis was
determined by cell cycle analysis as described under “Experimental
Procedures.” Data shown are the mean  S.E. of four different clones




GFP 2  1Aa 19  4B
GFP-FRNK 3/4b 39/43b
GFP-FAT 3  1A 34  4C
a Statistical differences were determined as described under “Exper-
imental Procedures.”
b Data shown are from two individual GFP-FRNK clones.
FIG. 10. Effect of GFP-FAT on DCVC-mediated decreases of
FAK phosphorylation. pkGFP and pkGFP-FAT cells were treated
with or without the indicated concentrations of DCVC in Hanks’/
HEPES buffer containing DPPD (10 M). At 4 and 8 h after treatment
samples were taken and analyzed for FAK phosphorylation using West-
ern blotting. Blots were stained for PY397-FAK and after stripping
stained for FAK. Shown are the data of pkGFP (clone 7) and pkGFP-
FAT (clone 8) that are representative for other pkGFP and pkGFP-FAT
clones. Data are representative for two independent experiments.























adhesions in pkGFP-FAT cells are much lower than in pkGFP
cells. A function of FAK in focal adhesion formation in LLC-
PK1 cells is also supported by the fact that early focal adhesion
organization is disrupted by GFP-FAT (Fig. 2). The increased
disruption of focal adhesion in pkGFP-FAT treated with DCVC
correlated with a drastic decrease of FAK phosphorylation on
Tyr397, suggesting a direct relationship between FAK phospho-
rylation status and focal adhesion organization.
Focal adhesion organization seems directly related to cell
survival signaling. Thus, our previous (15) and present obser-
vations indicate that focal adhesion disruption occurs prior to
the activation of caspase-3. We did not observe cells that were
positive for active caspase-3 and still possessed normal focal
adhesions. Rather, cells that were positive for active caspase-3
were fully fragmented (see Fig. 7). Also in other cell types
apoptosis caused by transient overexpression of FAT or FRNK
caused loss of focal adhesion independent of caspase activity
and prior to the appearance of apoptotic cells (31). Given the
importance of proper focal adhesion organization in the control
of cell death, what then are the signaling cascades downstream
from FAK that mediate protection against toxicant-induced
apoptosis? FAK phosphorylation on Tyr397 results in a docking
site for the SH2 domain of PI 3-kinase that seems important for
ECM-mediated survival through PKB (59). Our preliminary
data indicate that after DCVC treatment the phosphorylation
of PKB is lower in pkGFP-FAT cells than in pkGFP cells, which
seems directly related to the control of cell survival.2 Alterna-
tively, loss of FAK phosphorylation and consequently focal
adhesion organization may lead to loss of paxillin phosphoryl-
ation on Tyr31 and Tyr118 (Fig. 11), which are important dock-
ing sites for other signaling molecules, including Crk, that
plays an additional role in survival signaling (60).
Renal cell detachment plays an important role in the patho-
genesis of acute renal failure caused by either ischemia/reper-
fusion injury or chemical exposure that is associated with apo-
ptosis. Our present in vitro data support the notion that per-
turbations of cell-ECM signaling in renal epithelial cells lower
the set point for onset of apoptosis. Preliminary data from our
laboratory indicate that this may also be the case in vivo. Thus,
DCVC-induced acute renal failure is more pronounced in het-
erozygous FAK mice than in wild type littermates.3 This indi-
cates that in vivo FAK-mediated signaling may be a serious
option to modulate chemically induced renal injury; further
studies are required to investigate whether this is a general
phenomenon.
In conclusion, our study indicates a protective role for FAK in
the control of chemically induced apoptosis of renal epithelial
cells. Future studies should determine whether signal trans-
duction cascades downstream from FAK promote cell survival
3 B. van de Water and I. Tijdens, unpublished observations.
FIG. 11. Effect of GFP-FAT on DCVC-induced focal adhesion re-organization. pkGFP and pkGFP-FAT cells were plated on collagen-
coated glass coverslips and after overnight attachment and spreading were treated with or without DCVC (0.25 mM) in Hanks’/HEPES containing
DPPD (10 M). After 8 h cells were fixed and immunostained for paxillin and PY118-paxillin followed by confocal laser scan microscopy analysis
of GFP, paxillin, and PY118-paxillin. Data shown are from pkGFP (clone 7) and pkGFP-FAT (clone 8) and representative for other pkGFP and
pkGFP-FAT clones, respectively. Insets in the panels of PY118-paxillin pictures are enlargements of PY118-paxillin staining, and the corresponding
paxillin staining is shown as insets in the GFP pictures. Note that PY118-paxillin staining between untreated pkGFP and pkGFP-FAT cells is
comparable; in contrast, most of the PY118-paxillin staining is lost after DCVC treatment in pkGFP-FAT cells but not in pkGFP cells.
FIG. 12. Effect of GFP-FAT on dephosphorylation of paxillin
caused by DCVC. pkGFP and pkGFP-FAT cells were treated with or
without the indicated concentrations of DCVC in Hanks’/HEPES buffer
containing DPPD (10 M). At 4 and 8 h after treatment samples were
taken and analyzed for paxillin phosphorylation using Western blot-
ting. Blots were probed for PY31-paxillin or PY118-paxillin and thereaf-
ter stripped and stained and paxillin. Shown are the data of pkGFP
(clone 7) and pkGFP-FAT (clone 8) that are representative for other
pkGFP and pkGFP-FAT clones. Data are representative for two inde-
pendent experiments.























after renal cell injury and whether this is related to directly
affecting components of the apoptotic machinery or indirectly
through gene transcription regulation of pro- and/or anti-apo-
ptosis molecules.
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